/
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.
$3.46
+$0.07 (+2.06%)
Price from 17 days ago
The business is unprofitable at the operating level (-153.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 60.6% YoY with margins expanding 87.8pp.
Negative free cash flow of -$336M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$286M
▲ +60.6% YoY
Net Income (TTM)
-$354M
▼ -5.1% YoY
Op. Margin
-127.16%
▲ +87.8pp YoY
ROIC
-37.95%
▲ +1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$305M
▲ +7.6% YoY
Op. Cash Flow (TTM)
-$271M
▲ +14.3% YoY
Net Debt
-$266M
Net Cash Position
Cash & Equiv.
$313M
Continue Research